참고문헌
- Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, et al. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 2004;(420):21-27.
- Duffy A, Grof P, Robertson C, Alda M. The implications of genetics studies of major mood disorders for clinical practice. J Clin Psychiatry 2000;61:630-637. https://doi.org/10.4088/JCP.v61n0906
- Fava M. The role of the serotonergic and noradrenergic neurotransmitter systems in the treatment of psychological and physical symptoms of depression. J Clin Psychiatry 2003;64 Suppl 13:26-29.
- Fabbri C, Di Girolamo G, Serretti A. Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research. Am J Med Genet B Neuropsychiatr Genet 2013;162B:487-520.
- Stone EA, Lin Y, Rosengarten H, Kramer HK, Quartermain D. Emerging evidence for a central epinephrine-innervated alpha 1-adrenergic system that regulates behavioral activation and is impaired in depression. Neuropsychopharmacology 2003;28:1387-1399. https://doi.org/10.1038/sj.npp.1300222
- Huang K, Shi Y, Tang W, Tang R, Guo S, Xu Y, et al. No association found between the promoter variants of ADRA1A and schizophrenia in the Chinese population. J Psychiatr Res 2008;42:384-388. https://doi.org/10.1016/j.jpsychires.2007.02.008
- Kasper S. Efficacy of antidepressants in the treatment of severe depression: the place of mirtazapine. J Clin Psychopharmacol 1997;17 Suppl 1:19S-28S. https://doi.org/10.1097/00004714-199704001-00003
- Kent JM. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 2000;355:911-918. https://doi.org/10.1016/S0140-6736(99)11381-3
- Rogoz Z, Wrobel A, Dlaboga D, Maj J, Dziedzicka-Wasylewska M. Effect of repeated treatment with mirtazapine on the central alpha1- adrenergic receptors. J Physiol Pharmacol 2002;53:105-116.
- Rogoz Z, Skuza G, Legutko B. Repeated treatment with mirtazepine induces brain-derived neurotrophic factor gene expression in rats. J Physiol Pharmacol 2005;56:661-671.
- Kakui N, Yokoyama F, Yamauchi M, Kitamura K, Imanishi T, Inoue T, et al. Anxiolytic-like profile of mirtazapine in rat conditioned fear stress model: Functional significance of 5-hydroxytryptamine 1A receptor and alpha1-adrenergic receptor. Pharmacol Biochem Behav 2009;92:393-398. https://doi.org/10.1016/j.pbb.2008.12.022
- Freitas SR, Pereira AC, Floriano MS, Mill JG, Krieger JE. Association of alpha1a-adrenergic receptor polymorphism and blood pressure phenotypes in the Brazilian population. BMC Cardiovasc Disord 2008;8:40. https://doi.org/10.1186/1471-2261-8-40
- Ncbi.org [homepage on Internet]. USA: National Center for Biotechnology Information, U.S. National Library of Medicine. Available from: http://www.ncbi.nlm.nih.gov/gene/148#referencesequences.
- Shibata K, Hirasawa A, Moriyama N, Kawabe K, Ogawa S, Tsujimoto G. Alpha 1a-adrenoceptor polymorphism: pharmacological characterization and association with benign prostatic hypertrophy. Br J Pharmacol 1996;118:1403-1408. https://doi.org/10.1111/j.1476-5381.1996.tb15552.x
- Liu YR, Loh EW, Lan TH, Chen SF, Yu YH, Chang YH, et al. ADRA1A gene is associated with BMI in chronic schizophrenia patients exposed to antipsychotics. Pharmacogenomics J 2010;10:30-39. https://doi.org/10.1038/tpj.2009.55
- Klotsman M, Weinberg CR, Davis K, Binnie CG, Hartmann KE. A case-based evaluation of SRD5A1, SRD5A2, AR, and ADRA1A as candidate genes for severity of BPH. Pharmacogenomics J 2004;4:251-259. https://doi.org/10.1038/sj.tpj.6500248
- Clark DA, Mancama D, Kerwin RW, Arranz MJ. Expression of the alpha1A-adrenergic receptor in schizophrenia. Neurosci Lett 2006;401:248-251. https://doi.org/10.1016/j.neulet.2006.03.025
- Elia J, Capasso M, Zaheer Z, Lantieri F, Ambrosini P, Berrettini W, et al. Candidate gene analysis in an on-going genome-wide association study of attention-deficit hyperactivity disorder: suggestive association signals in ADRA1A. Psychiatr Genet 2009;19:134-141. https://doi.org/10.1097/YPG.0b013e32832a5043
- Vargas-Alarcon G, Fragoso JM, Cruz-Robles D, Vargas A, Martinez A, Lao-Villadoniga JI, et al. Association of adrenergic receptor gene polymorphisms with different fibromyalgia syndrome domains. Arthritis Rheum 2009;60:2169-2173. https://doi.org/10.1002/art.24655
- Burcescu I, Wigg K, Gomez L, King N, Vetro A, Kiss E, et al. Association study of the adrenergic receptors and childhood-onset mood disorders in Hungarian families. Am J Med Genet B Neuropsychiatr Genet 2006;141B:227-233. https://doi.org/10.1002/ajmg.b.30292
- Lario S, Calls J, Cases A, Oriola J, Torras A, Rivera F. MspI identifies a biallelic polymorphism in the promoter region of the alpha 2A-adrenergic receptor gene. Clin Genet 1997;51:129-130.
- Small KM, Brown KM, Seman CA, Theiss CT, Liggett SB. Complex haplotypes derived from noncoding polymorphisms of the intronless alpha2A-adrenergic gene diversify receptor expression. Proc Natl Acad Sci U S A 2006;103:5472-5477. https://doi.org/10.1073/pnas.0601345103
- Yoshida K, Naito S, Takahashi H, Sato K, Ito K, Kamata M, et al. Monoamine oxidase: A gene polymorphism, tryptophan hydroxylase gene polymorphism and antidepressant response to fluvoxamine in Japanese patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:1279-1283. https://doi.org/10.1016/S0278-5846(02)00267-1
-
Shorter D, Nielsen DA, Huang W, Harding MJ, Hamon SC, Kosten TR. Pharmacogenetic randomized trial for cocaine abuse: disulfiram and
${\alpha}1A$ -adrenoceptor gene variation. Eur Neuropsychopharmacol 2013;23:1401-1407. https://doi.org/10.1016/j.euroneuro.2013.05.014 - Keller MB. Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond. JAMA 2003;289:3152-3160. https://doi.org/10.1001/jama.289.23.3152
- Clark DA, Arranz MJ, Mata I, Lopez-Ilundain J, Perez-Nievas F, Kerwin RW. Polymorphisms in the promoter region of the alpha1A-adrenoceptor gene are associated with schizophrenia/schizoaffective disorder in a Spanish isolate population. Biol Psychiatry 2005;58:435-439. https://doi.org/10.1016/j.biopsych.2005.04.051
- Arnsten AF. Adrenergic targets for the treatment of cognitive deficits in schizophrenia. Psychopharmacology (Berl) 2004;174:25-31.
- Fallin MD, Lasseter VK, Liu Y, Avramopoulos D, McGrath J, Wolyniec PS, et al. Linkage and association on 8p21.2-p21.1 in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2011;156:188-197. https://doi.org/10.1002/ajmg.b.31154
- Birnbaum SG, Yuan PX, Wang M, Vijayraghavan S, Bloom AK, Davis DJ, et al. Protein kinase C overactivity impairs prefrontal cortical regulation of working memory. Science 2004;306:882-884. https://doi.org/10.1126/science.1100021
- Siris SG. Depression in schizophrenia: perspective in the era of "Atypical" antipsychotic agents. Am J Psychiatry 2000;157:1379-1389. https://doi.org/10.1176/appi.ajp.157.9.1379
- de Figueiredo JM. Depression and demoralization: phenomenologic differences and research perspectives. Compr Psychiatry 1993;34:308-311. https://doi.org/10.1016/0010-440X(93)90016-W